1887
Volume 2023, Issue 4
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

The coronavirus disease (COVID-19) has resulted in more than 6 million deaths worldwide since it was identified in 2019, resulting in significant morbidity and mortality. The impact of COVID-19 on the acquisition of multi-drug-resistant organisms (MDRO) remains uncertain. This study aims to investigate the effect of COVID-19 on the acquisition of MDRO in the intensive care unit (ICU).

A single-center, retrospective observational study at Wollongong ICU compared the acquisition rate of MDRO, especially vancomycin-resistant enterococci (VRE) and methicillin-resistant (MRSA), pre- and post-COVID.

There was a significant increase in MDRO incidence post-COVID compared to pre-COVID, with incidence rates increasing from 1.6% to 4.56%, especially in MRSA acquisitions, which increased from 0.91% to 5.71%. This increase was associated with a longer ICU length of stay (LOS) but did not have a significant effect on hospital LOS or mortality. The increased incidence of MDRO was potentially related to increased antibiotic use and staffing changes during the COVID period.

COVID-19 significantly impacted the acquisition of MDRO, particularly MRSA.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2023.33
2023-11-01
2024-07-25
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2023/4/jemtac.2023.33.html?itemId=/content/journals/10.5339/jemtac.2023.33&mimeType=html&fmt=ahah

References

  1. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2022 Oct. Treasure Island, FL: StatPearls Publishing.
    [Google Scholar]
  2. Bogossian EG, Taccone FS, Izzi A, Yin N, Garufi A, Hublet S, et al. The acquisition of multidrug-resistant bacteria in patients admitted to COVID-19 intensive care inits: A monocentric retrospective case control study. Microorganisms. 2020; 8:(11):1821. doi: [Crossref].
    https://doi.org/10.3390/microorganisms8111821 [Google Scholar]
  3. Fernández P, Moreno L, Yagüe G, Andreu E, Jara R, Segovia M. Colonization by multidrug-resistant microorganisms in ICU patients during the COVID-19 pandemic. Med Intens. 2021; 45:(5):313–5. doi: [Crossref].
    https://doi.org/10.1016/j.medine.2021.04.006 [Google Scholar]
  4. Cole J, Barnard E. The impact of the COVID-19 pandemic on healthcare acquired infections with multidrug resistant organisms. Am J Infect Control. 2021; 49:(5):653–4. doi: [Crossref].
    https://doi.org/10.1016/j.ajic.2020.09.013 [Google Scholar]
  5. Polly M, de Almeida, BL, Lennon RP, Cortês MF, Costa SF, Guimarães T. Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil. Am J Infect Control. 2022; 50:(1):32–8. doi: [Crossref].
    https://doi.org/10.1016/j.ajic.2021.09.018 [Google Scholar]
  6. Bork JT, Leekha S, Claeys K, Seung H, Tripoli M, Amoroso A, et al. Change in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019. Infect Control Hosp Epidemiol. 2021; 42:(9):1115–7. doi: [Crossref].
    https://doi.org/10.1017/ice.2020.1360 [Google Scholar]
  7. Wozniak TM, Dyda A, Merlo G, Hall L. Disease burden, associated mortality and economic impact of antimicrobial resistant infections in Australia. Lancet Reg Health. West Pac. 2022; 27::100521. doi: [Crossref].
    https://doi.org/10.1016/j.lanwpc.2022.100521 [Google Scholar]
  8. Litton E, Huckson S, Chavan S, Bucci T, Holley A, Everest E, et al. Increasing ICU capacity to accommodate higher demand during the COVID-19 pandemic. Med J Austr. 2021; 215:(11):513–7. doi: [Crossref].
    https://doi.org/10.5694/mja2.51318 [Google Scholar]
  9. Basak S, Singh P, Rajurkar M. Multidrug resistant and extensively drug resistant bacteria: A study. J Pathog. 2016; 2016::4065603. doi: [Crossref].
    https://doi.org/10.1155/2016/4065603 [Google Scholar]
  10. Paz V, Paniagua M, Santillán A, Alaniz M, D’Agostino L, Orellana R, et al. Hospital environment hygiene nurse: A key player to reduce healthcare associated infections by multi-resistant organisms. Infect Prev Pract. 2020; 2:(1):100030. doi: [Crossref].
    https://doi.org/10.1016/j.infpip.2019.100030 [Google Scholar]
  11. Beyersmann J, Gastmeier P, Schumacher M. Incidence in ICU populations: How to measure and report it? Intens Care Med. 2014; 40::871–6. doi: [Crossref].
    https://doi.org/10.1007/s00134-014-3279-7 [Google Scholar]
  12. Cope C, Irene W. Multidrug-resistant organisms. 2021. Available online at: www.sahealth.sa.gov.au/HAIstatistics
    [Google Scholar]
  13. O’Toole RF. The interface between COVID-19 and bacterial healthcare-associated infections. Clin Microbiol Infect. 2021; 27:(12):1772–6. doi: [Crossref].
    https://doi.org/10.1016/j.cmi.2021.06.001 [Google Scholar]
  14. Hu S, You Y, Zhang S, Tang J, Chen C, Wen W, et al. Multidrug-resistant infection in COVID-19 patients: A meta-analysis. J Infect. 2022; 86:(1):66−117. doi: [Crossref].
    https://doi.org/10.1016/j.jinf.2022.10.043 [Google Scholar]
  15. Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, et al. (2021). Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021. Prev Chronic Dis. 2021; 18::E66. doi: [Crossref].
    https://doi.org/10.5888/PCD18.210123 [Google Scholar]
  16. World Health Organization [WHO]. Evidence of Hand Hygiene to Reduce Transmission and Infections by Multi-Drug Resistant Organisms in Health-Care Settings. 2023. Available online at: https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/infection-prevention-and-control/mdro-literature-review.pdf?sfvrsn=88dd45c7_2 (accessed February 28, 2023).
    [Google Scholar]
  17. Okamoto K, Rhee Y, Schoeny M, Lolans K, Cheng J, Reddy S, Popovich K. Impact of doffing errors on healthcare worker self-contamination when caring for patients on contact precautions. Infect Control Hosp Epidemiol. 2019; 40:(5):559−65. doi: [Crossref].
    https://doi.org/10.1017/ice.2019.33 [Google Scholar]
  18. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. (2022). Atlanta, GA: Centers for Disease Control and Prevention. doi: [Crossref].
    https://doi.org/10.15620/cdc:117915 [Google Scholar]
  19. Conway Morris A, Kohler K, de Corte T, Ercole A, de Grooth H-J, Elbers PWG, et al. Co-infection and ICU-acquired infection in COIVD-19 ICU patients: A secondary analysis of the UNITE-COVID data set. Crit Care (London, England). 2022; 26:(1):236. doi: [Crossref].
    https://doi.org/10.1186/s13054-022-04108-8 [Google Scholar]
  20. Nandi A, Pecetta S, Bloom DE. Global antibiotic use during the COVID-19 pandemic: Analysis of pharmaceutical sales data from 71 countries, 2020-2022. EClinicalMedicine. 2023; 57::101848. doi: [Crossref].
    https://doi.org/10.1016/j.eclinm.2023.101848 [Google Scholar]
  21. Alshaikh FS, Godman B, Sindi ON, Seaton RA, Kurdi A. Prevalence of bacterial coinfection and patterns of antibiotics prescribing in patients with COVID-19: A systematic review and meta-analysis. PLoS One. 2022; 7:(8):e0272375. doi: [Crossref].
    https://doi.org/10.1371/journal.pone.0272375 [Google Scholar]
  22. Langford BJ, So M, Raybardhan S, Leung V, Soucy J-PR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: Rapid review and meta-analysis. Clin Microbiol Infect. 2021; 27:(4):520–31. doi: [Crossref].
    https://doi.org/10.1016/j.cmi.2020.12.018 [Google Scholar]
  23. Vaughn VM, Gandhi TN, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with Coronavirus Disease 2019 (COVID-19): A multi-hospital Cohort Study. Clin Infect Dis. 2021; 72:(10):e533–41. doi: [Crossref].
    https://doi.org/10.1093/cid/ciaa1239 [Google Scholar]
  24. Hugonnet S, Harbarth S, Sax H, Duncan RA, Pittet D. Nursing resources: A major determinant of nosocomial infection? Curr Opin Infect Dis. 2004; 17:(4):329−33. doi: [Crossref].
    https://doi.org/10.1097/01.qco.0000136931.83167.d2 [Google Scholar]
  25. Jackson M, Chiarello LA, Gaynes RP, Gerberding JL. Nurse staffing and health care-associated infections: Proceedings from a working group meeting. Am J Infect Control. 2022; 30:(4):199−206. doi: [Crossref].
    https://doi.org/10.1067/mic.2002.123416 [Google Scholar]
  26. Stone PW, Clarke SP, Cimiotti J, Correa-de-Araujo R. Nurses’ working conditions: Implications for infectious disease. Emerg Infect Dis. 2004; 10:(11):1984–9. doi: [Crossref].
    https://doi.org/10.3201/eid1011.040253 [Google Scholar]
/content/journals/10.5339/jemtac.2023.33
Loading
/content/journals/10.5339/jemtac.2023.33
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error